[go: up one dir, main page]

DK20984D0 - Fremgangsmade til fremstilling af et oensket modent protein i en hvirveldyrvaertscelle,polycistromisk udtrykkelsesvektor for det oenskede protein, fremgangsmade til selektering af transfilerede hvirveldyrceller og hvirveldyrcellekultur transformeret med vektoren - Google Patents

Fremgangsmade til fremstilling af et oensket modent protein i en hvirveldyrvaertscelle,polycistromisk udtrykkelsesvektor for det oenskede protein, fremgangsmade til selektering af transfilerede hvirveldyrceller og hvirveldyrcellekultur transformeret med vektoren

Info

Publication number
DK20984D0
DK20984D0 DK0209/84A DK20984A DK20984D0 DK 20984 D0 DK20984 D0 DK 20984D0 DK 0209/84 A DK0209/84 A DK 0209/84A DK 20984 A DK20984 A DK 20984A DK 20984 D0 DK20984 D0 DK 20984D0
Authority
DK
Denmark
Prior art keywords
protein
procedure
expression vector
transfiled
polycistromisic
Prior art date
Application number
DK0209/84A
Other languages
English (en)
Other versions
DK173928B1 (da
DK20984A (da
Inventor
Arthur David Levinson
Christian Clinton Simonsen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK20984D0 publication Critical patent/DK20984D0/da
Publication of DK20984A publication Critical patent/DK20984A/da
Priority to DK199501455A priority Critical patent/DK173671B1/da
Application granted granted Critical
Publication of DK173928B1 publication Critical patent/DK173928B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Separation, Sorting, Adjustment, Or Bending Of Sheets To Be Conveyed (AREA)
  • Sheets, Magazines, And Separation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyurethanes Or Polyureas (AREA)
DK198400209A 1983-01-19 1984-01-18 Fremgangsmåde til fremstilling af et ønsket modent protein i en hvirveldyrværtscelle, polycistronisk ekspressionsvektor for det ønskede protein og hvirveldyrcellekultur transformeret med vektoren DK173928B1 (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK199501455A DK173671B1 (da) 1983-01-19 1995-12-21 Fremgangsmåde til selektion af transficerede hvirveldyrceller

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/459,152 US4713339A (en) 1983-01-19 1983-01-19 Polycistronic expression vector construction
US45915283 1983-01-19

Publications (3)

Publication Number Publication Date
DK20984D0 true DK20984D0 (da) 1984-01-18
DK20984A DK20984A (da) 1984-07-20
DK173928B1 DK173928B1 (da) 2002-02-25

Family

ID=23823622

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198400209A DK173928B1 (da) 1983-01-19 1984-01-18 Fremgangsmåde til fremstilling af et ønsket modent protein i en hvirveldyrværtscelle, polycistronisk ekspressionsvektor for det ønskede protein og hvirveldyrcellekultur transformeret med vektoren

Country Status (13)

Country Link
US (1) US4713339A (da)
EP (1) EP0117058B1 (da)
JP (3) JPH0630609B2 (da)
KR (1) KR840007253A (da)
AT (1) ATE46536T1 (da)
AU (1) AU578011B2 (da)
CA (1) CA1301675C (da)
DE (1) DE3479815D1 (da)
DK (1) DK173928B1 (da)
ES (1) ES529022A0 (da)
IE (1) IE55852B1 (da)
NZ (1) NZ206841A (da)
ZA (1) ZA84377B (da)

Families Citing this family (309)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
ZA851626B (en) * 1984-03-06 1986-10-29 Lilly Co Eli Recombinant dna expression vectors and method for gene expression
GB8522977D0 (en) * 1985-09-17 1985-10-23 Fujisawa Pharmaceutical Co Production of insulin-like growth factor 1
IL71691A (en) * 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
CA1275954C (en) * 1984-08-31 1990-11-06 Hing Cheug Wong 3'-expression enhancing fragments and method
IL80511A0 (en) * 1985-11-05 1987-02-27 Genetics Inst Multiply amplifiable vectors for high level expression of exogenous dna
DK13087A (da) * 1986-01-13 1987-07-14 Genex Corp Gensekvens til fremstilling af human serumalbumin i bacillus
CA1297434C (en) * 1986-04-14 1992-03-17 Kenji Murakami Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
JP2585532B2 (ja) * 1986-05-10 1997-02-26 三井東圧化学株式会社 動物細胞の形質転換体及びそれを得る方法並びにその形質転換体を用いてｔ−ＰＡを生産する方法
AU613876B2 (en) * 1986-10-01 1991-08-15 Merck & Co., Inc. Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
WO1988005466A2 (en) * 1987-01-15 1988-07-28 Codon Tandem gene eukaryotic expression vectors
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5215896A (en) * 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US5876962A (en) * 1987-08-12 1999-03-02 Natural Environment Research Council Expression vectors for the synthesis of proteins and plasmid replicons and sequence cassettes for use in constructing such vectors
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JP2576200B2 (ja) * 1988-03-09 1997-01-29 味の素株式会社 生理活性タンパク質の製造法
US4892871A (en) * 1988-04-12 1990-01-09 The General Hospital Corporation Azido-substituted octopamine agonists and the use thereof to control invertebrate pests
WO1990001550A1 (en) * 1988-07-29 1990-02-22 Zymogenetics, Inc. High efficiency translation of polycistronic messages in eucaryotic cells
US20020168750A1 (en) * 1988-12-23 2002-11-14 James Rasmussen Enzymatically active recombinant glucocerebrosidase
US5549892A (en) * 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) * 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5545727A (en) 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
NZ233642A (en) 1989-05-10 1992-12-23 Somatogenetics Int Linked hemoglobin subunits, preparation by genetic engineering and linker assay
EP0483249B1 (en) * 1989-07-18 2003-04-23 OSI Pharmaceuticals, Inc. Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US6203976B1 (en) * 1989-07-18 2001-03-20 Osi Pharmaceuticals, Inc. Methods of preparing compositions comprising chemicals capable of transcriptional modulation
US6475787B1 (en) * 1989-07-28 2002-11-05 Wyeth Method for producing monoclonal antibodies
US7247475B2 (en) * 1989-07-28 2007-07-24 Wyeth Method for producing monoclonal antibodies
DE69130494T2 (de) * 1990-06-11 1999-07-08 Nakamura, Toshikazu, Fukuoka Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
AU1536392A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
WO1992013092A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of hematopoietic growth factor genes
AU1469292A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
JPH0516500U (ja) * 1991-08-09 1993-03-02 富士通テン株式会社 車載用機器の取付構造
ATE168014T1 (de) * 1991-11-08 1998-07-15 Somatogen Inc Hämoglobine als arzneimittelabgabesystem
WO1994021669A1 (en) * 1993-03-18 1994-09-29 Medclone, Inc. Antigen related to inflammatory diseases
US5639940A (en) 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
JPH11514976A (ja) 1995-09-08 1999-12-21 ジェネンテク・インコーポレイテッド Ｖｅｇｆ−関連タンパク質
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
JP2000507829A (ja) 1996-04-01 2000-06-27 ジェネンテック インコーポレーテッド Ａｐｏ―２ｌｉおよびａｐｏ―３アポトーシスポリペプチド
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
WO1998033924A1 (en) 1997-01-31 1998-08-06 Genentech, Inc. O-fucosyltransferase
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
WO1999027098A2 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
DK0981618T4 (da) 1997-05-15 2011-11-21 Genentech Inc Anti-Apo-2-antistof
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6291643B1 (en) 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
JP2002508663A (ja) 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Ａｐｏ−２ＤｃＲ
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ES2306480T3 (es) 1997-09-18 2008-11-01 Genentech, Inc. Polipeptido dcr3, un homologo de tnfr.
EP1967587A1 (en) 1997-10-10 2008-09-10 Genentech, Inc. APO-3 Ligand
ES2316173T3 (es) 1997-10-29 2009-04-01 Genentech, Inc. Genes inducibles por wnt-1.
AU1288399A (en) 1997-10-29 1999-05-17 Genentech Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
CA2318029C (en) 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
AU758353B2 (en) 1998-03-17 2003-03-20 Genentech Inc. Polypeptides homologous to VEGF and BMP1
EP1076703B2 (en) 1998-05-15 2010-12-15 Genentech, Inc. Therapeutic uses of il-17 homologous polypeptides
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
WO2001051635A2 (en) 2000-01-13 2001-07-19 Genentech, Inc. Novel stra6 polypeptides
CA2343839C (en) 1998-09-23 2012-09-11 Zymogenetics, Inc. Cytokine receptor zalpha11
DE69939330D1 (de) 1998-12-07 2008-09-25 Zymogenetics Inc Wachstumsfaktor-homologe zvegf-3
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
EP1141299A2 (en) 1998-12-23 2001-10-10 Genentech, Inc. Il-1 related polypeptides
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DE60043626D1 (de) 1999-01-07 2010-02-11 Zymogenetics Inc Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
EP1881070B1 (en) 1999-03-09 2012-10-03 Zymogenetics, Inc. Human cytokine as ligand of the zalpha receptor and uses thereof
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
DE60043322D1 (de) 1999-06-15 2009-12-24 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
MXPA01013236A (es) 1999-06-28 2002-06-21 Genentech Inc Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
EP1669371A3 (en) 1999-12-01 2006-06-21 Genentech, Inc. Composition and methods for the diagnosis of tumours
EP1897945B1 (en) 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
DE60043944D1 (de) 1999-12-23 2010-04-15 Zymogenetics Inc Zytokin zcyt018
IL150755A0 (en) 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
ATE343562T1 (de) 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
WO2004043361A2 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2709771A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002000721A2 (en) 2000-06-26 2002-01-03 Zymogenetics, Inc. Cytokine receptor zcytor17
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1299352B1 (en) 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
ATE404670T1 (de) 2000-06-30 2008-08-15 Zymogenetics Inc Allelische variante des interferon-ähnlichen proteins zcyto21
KR100545945B1 (ko) 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
WO2002014473A2 (en) 2000-08-15 2002-02-21 Board Of Trustees Of The University Of Illinois Animals expressing exogenous igf-i in their milk
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL154520A0 (en) 2000-09-13 2003-09-17 Novo Nordisk As Human coagulation factor vii variants
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
EP1373493B1 (en) 2001-03-22 2013-07-31 Novo Nordisk Health Care AG Coagulation factor vii derivative
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002318371B2 (en) 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BR0210721A (pt) 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
JP4361791B2 (ja) 2001-08-29 2009-11-11 ジェネンテック・インコーポレーテッド マイトジェン活性を有するＢｖ８核酸及びポリペプチド
WO2003024392A2 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002333211B2 (en) 2001-09-27 2008-05-08 Novo Nordisk Health Care Ag Human coagulation factor VII polypeptides
CA2461292A1 (en) 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
EP2305314B1 (en) 2001-10-10 2015-12-23 ratiopharm GmbH Remodelling and glycoconjugation of antibodies
AU2002336676A1 (en) 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
IL161812A0 (en) 2001-11-13 2005-11-20 Genentech Inc Apo2 ligand/trail formulations
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
AU2002364956C1 (en) 2001-11-16 2009-05-28 Biogen Idec Inc. Polycistronic expression of antibodies
WO2003057160A2 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK2230299T3 (da) 2002-01-18 2012-03-26 Zymogenetics Inc Hidtil ukendt cytokin ZCYTOR17-ligand
WO2004003140A2 (en) 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK1485477T3 (da) 2002-02-25 2009-08-10 Genentech Inc Hidtil ukendt type-1-cytokinreceptor GLM-R
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
CN101676728A (zh) 2002-04-19 2010-03-24 津莫吉尼蒂克斯公司 细胞因子受体
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003243400B2 (en) 2002-06-07 2009-10-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
EP2383278A1 (en) 2002-07-08 2011-11-02 Genentech, Inc. Method to determine B cell mediated diseases
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
EP1539228B1 (en) 2002-09-11 2010-12-29 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2322203A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004046340A2 (en) * 2002-11-14 2004-06-03 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
CA2504144A1 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
CN1761747A (zh) 2003-03-18 2006-04-19 诺和诺德医疗保健公司 生产含有gla残基的丝氨酸蛋白酶的方法
CA2519241A1 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK2335725T3 (da) 2003-04-04 2017-01-23 Genentech Inc Højkoncentrerede antistof- og proteinformuleringer
WO2004092329A2 (en) * 2003-04-08 2004-10-28 Galenica Pharmaceuticals, Inc. Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
DK1624891T4 (da) 2003-05-06 2013-07-15 Biogen Idec Hemophilia Inc Kimære koagulationsfaktor Fc proteiner til behandling af hæmofili
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
NZ543712A (en) 2003-06-05 2008-06-30 Genentech Inc Combination therapy for B cell disorders
KR20060031618A (ko) 2003-06-10 2006-04-12 엔에스진 에이/에스 뉴블라스틴 분비 증진 방법
PL1641822T3 (pl) 2003-07-08 2013-10-31 Genentech Inc Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
JP4808157B2 (ja) 2003-08-07 2011-11-02 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９の均一な調製物
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4751326B2 (ja) 2003-09-04 2011-08-17 メダレックス インコーポレイテッド 発現ベクター
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
DE602004024921D1 (de) 2003-11-17 2010-02-11 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
US7601516B2 (en) * 2004-01-28 2009-10-13 Syntomix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
US7381794B2 (en) 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
KR101222254B1 (ko) 2004-07-26 2013-01-16 제넨테크, 인크. 간세포 성장 인자 활성화를 조정하기 위한 조성물 및 방법
WO2006012644A2 (en) 2004-07-29 2006-02-02 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US20060286092A1 (en) 2005-05-12 2006-12-21 Zeren Gao Methods of using pNKp30, a member of the B7 family, to modulate the immune system
AU2006255686A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
CA2618765A1 (en) * 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP1969127B8 (en) 2005-12-21 2017-12-13 Aptevo BioTherapeutics LLC Method of producing biologically active vitamin k dependent proteins by recombinant methods
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
CN101501216B (zh) 2006-03-06 2013-10-02 胡玛基因公司 制备重组人凝血酶的方法
US7566565B2 (en) * 2006-03-24 2009-07-28 Syntonix Pharmaceuticals, Inc. PC5 as a factor IX propeptide processing enzyme
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
EP3026123A1 (en) 2006-04-27 2016-06-01 Klaritos, Inc. Method and kit for predicting antibody therapy
JP2009537563A (ja) * 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
WO2007135182A2 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Factor ix analogues having prolonged in vivo half life
JP2009542225A (ja) 2006-06-30 2009-12-03 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミシガン 組換え法によりｆｖｉｉｉタンパク質を生産する方法
PL2041270T3 (pl) 2006-07-13 2014-04-30 Wyeth Llc Wytwarzanie glikoprotein
EP2078040B1 (en) 2006-11-02 2017-06-28 Daniel J. Capon Methods of producing hybrid polypeptides with moving parts
WO2008066658A2 (en) 2006-11-03 2008-06-05 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
WO2008103962A2 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
RU2009132986A (ru) 2007-03-02 2011-04-10 Уайт (Us) Применение меди и глутамата в культуре клеток для производства полипептидов
EP2517714A1 (en) 2007-04-26 2012-10-31 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
EP2641618A3 (en) 2007-07-16 2013-10-23 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
CN111499748A (zh) 2007-07-16 2020-08-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
KR20100040951A (ko) * 2007-08-09 2010-04-21 신토닉스 파마수티칼스, 인코포레이티드 면역조절성 펩티드
PL2233149T3 (pl) 2007-10-16 2016-08-31 Zymogenetics Inc Kombinacja przezbłonowego aktywatora i ligandu cyklofiliny (taci) oraz przeciwciała anty-cd20 do leczenia chorób autoimmunologicznych
HUE029869T2 (en) 2008-01-31 2017-04-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
US9441034B2 (en) 2008-03-27 2016-09-13 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRβ and VEGF-A
EP3605088A1 (en) 2008-04-09 2020-02-05 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN102131517B (zh) 2008-06-27 2014-12-17 津莫吉尼蒂克斯公司 可溶性杂合Fc γ受体和相关的方法
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
MX347112B (es) 2008-09-15 2017-04-12 Genentech Inc Composiciones y metodos para regular osmolaridad celular.
US9702877B2 (en) 2008-10-31 2017-07-11 Quest Diagnostics Investments Incorporated BCR-ABL variants
ES2552325T3 (es) * 2008-12-22 2015-11-27 National University Corporation Hokkaido University Vector de expresión para producción a gran escala de proteína derivada de genes foráneos usando células animales, y uso del mismo
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
TW201038286A (en) 2009-04-01 2010-11-01 Genentech Inc Anti-FcRH5 antibodies and immunoconjugates and methods of use
BR112012001070B1 (pt) 2009-07-17 2022-05-03 Omeros Corporation Composição de polipeptídeo associado à ficolina e uso da mesma
PT2464725T (pt) 2009-08-11 2020-05-21 Hoffmann La Roche Produção de proteínas em meios de cultura celular isentos de glutamina
JP2013502458A (ja) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
US9488656B2 (en) 2009-09-30 2016-11-08 Quest Diagnostics Investments Incorporated BCR-ABL truncation mutations
WO2011047267A1 (en) 2009-10-15 2011-04-21 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
JP5851410B2 (ja) 2009-10-30 2016-02-03 シーエヌジェイ ホールディングス、インク． 組換えビタミンｋ依存性タンパク質の生成法
AR078986A1 (es) 2009-11-12 2011-12-14 Genentech Inc Un metodo para promover la densidad de espinas dendriticas
JP5856065B2 (ja) 2009-11-30 2016-02-09 ジェネンテック， インコーポレイテッド 腫瘍の診断と治療のための組成物と方法
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
BR112012020373A8 (pt) 2010-02-23 2018-01-02 Genentech Inc anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
EP3815708A1 (en) 2010-03-05 2021-05-05 Omeros Corporation Chimeric inhibitor molecules of complement activation
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EA022932B1 (ru) 2010-06-09 2016-03-31 Зимодженетикс, Инк. Димерные слитые белки vstm3 и связанные с ними композиции и способы
US20130150286A1 (en) 2010-06-25 2013-06-13 Jean-Claude Sirard Methods and pharmaceutical compositions for the treatment of respiratory tract infections
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN103797026A (zh) 2010-09-15 2014-05-14 阿利吉那科技有限公司 由木质素衍生的化合物生物生产芳香族化学品
US8603740B2 (en) 2010-12-29 2013-12-10 Quest Diagnostics Investments Incorporated BCR-ABL1 splice variants and uses thereof
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
EP2755675B1 (en) 2011-09-12 2018-06-06 Amunix Operating Inc. Glucagon-like peptide-2 compositions and methods of making and using same
JP6400473B2 (ja) 2011-10-21 2018-10-03 ファイザー・インク 細胞培養を改善するための鉄の添加
US8748097B1 (en) 2011-12-02 2014-06-10 President And Fellows Of Harvard College Identification of agents for treating calcium disorders and uses thereof
PL2804623T3 (pl) 2012-01-12 2020-03-31 Bioverativ Therapeutics Inc. Chimeryczne polipeptydy czynnika viii i ich zastosowania
EP3597764A3 (en) 2012-02-01 2020-05-06 SGI-DNA, Inc. Material and methods for the synthesis of error-minimized nucleic acid molecules
US11787844B2 (en) 2012-02-09 2023-10-17 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
KR102097263B1 (ko) 2012-02-15 2020-04-06 바이오버라티브 테라퓨틱스 인크. Viii 인자 조성물 및 이를 제조하고 사용하는 방법
EP3549953A1 (en) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9657310B2 (en) 2012-04-27 2017-05-23 Jcr Pharmaceuticals Co., Ltd. Expression vector
WO2013163606A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vascular endothelial growth factor antagonists and methods for their use
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
CN104704118A (zh) 2012-10-15 2015-06-10 诺和诺德保健Ag（股份有限公司） 凝血因子vii多肽
AU2013348029A1 (en) 2012-11-20 2015-07-02 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX proteins
WO2014115087A2 (en) 2013-01-22 2014-07-31 Cencor Biotech Ltd. A method for the preparation of recombinant human prothrombin and fibrinogen
EP2970422B1 (en) 2013-03-15 2018-04-18 F.Hoffmann-La Roche Ag Il-22 polypeptides and il-22 fc fusion proteins and methods of use
PT3611180T (pt) 2013-03-15 2022-03-15 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
KR102714760B1 (ko) 2013-06-28 2024-10-11 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
MX2016006167A (es) 2013-11-15 2016-08-08 Genentech Inc Metodos para la inactivacion viral usando detergentes ecologico.
KR102409250B1 (ko) 2014-01-10 2022-06-14 바이오버라티브 테라퓨틱스 인크. 인자 viii 키메라 단백질 및 이들의 용도
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
EP3116486B1 (en) 2014-03-14 2019-12-04 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
EP4512889A2 (en) 2014-03-19 2025-02-26 Pfizer Inc. Method of cell culture
EP3233107B1 (en) 2014-12-09 2021-01-27 Wentao Zhang Nbp158 and uses thereof
EP3253786A4 (en) 2015-02-06 2018-10-17 The University of North Carolina at Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
MX2017014872A (es) 2015-05-22 2018-07-06 Csl Behring Recombinant Facility Ag Metodos para preparar factor de von willebrand modificado.
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
EP3328881B1 (en) 2015-09-08 2019-08-28 Theripion, Inc. Apoa-1 fusion polypeptides and related compositions and methods
EP3353313B1 (en) 2015-09-23 2024-08-07 Pfizer Inc. Cells and method of cell culture
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
CN108472338B (zh) 2016-01-07 2022-12-30 康诺贝林伦瑙有限公司 突变的截短的von Willebrand因子
EP3196295A1 (en) 2016-01-25 2017-07-26 Albert-Ludwigs-Universität Freiburg Method of producing renal cells from fibroblasts
HRP20241328T1 (hr) 2016-04-05 2024-12-20 Pfizer Inc. Postupak kulture stanica
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
ES2869339T3 (es) 2016-11-11 2021-10-25 CSL Behring Lengnau AG Polipéptidos del factor von Willebrand truncados para el tratamiento de la hemofilia
EP3538134B1 (en) 2016-11-11 2021-12-29 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
CA3068098A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
MX2020000583A (es) 2017-07-20 2020-09-10 Aptevo Res & Development Llc Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados.
BR112020012364A2 (pt) 2017-12-20 2020-11-24 Harbour Biomed (Shanghai) Co., Ltd anticorpos de ligação a ctla-4 e usos dos mesmos
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
CN111801346B (zh) 2017-12-27 2024-08-09 免疫实验室私人有限公司 重组多肽及其使用方法
EP3743088B1 (en) 2018-01-26 2022-10-12 F. Hoffmann-La Roche AG Il-22 fc compositions and methods of use
SG11202006259SA (en) 2018-01-26 2020-08-28 Genentech Inc Il-22 fc fusion proteins and methods of use
JP2021514354A (ja) 2018-02-21 2021-06-10 ジェネンテック， インコーポレイテッド ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
EP3788071A1 (en) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.
CN112789504A (zh) 2018-07-13 2021-05-11 瓦克特诊断有限责任公司 使用重组疟疾蛋白var2csa分离胎儿来源的循环细胞
JP2022513702A (ja) 2018-12-06 2022-02-09 ファイザー・インク 阻害剤産生が低下した細胞およびその使用方法
EP3994162A1 (en) 2019-07-04 2022-05-11 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP4021512A1 (en) 2019-08-26 2022-07-06 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
EP4168034A1 (en) 2020-06-22 2023-04-26 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and combinations for use in the treatment of cancer
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
JP2023540098A (ja) 2020-09-03 2023-09-21 チェン アーヴィン エス．ワイ． 可溶性アルカリホスファターゼ構築物及び可溶性アルカリホスファターゼ構築物をコードするポリヌクレオチドを含む発現ベクター
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
JP2024507220A (ja) 2021-02-19 2024-02-16 セリピオン， インコーポレイテッド パラオキソナーゼ融合ポリペプチドならびに関連する組成物および方法
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法
EP4380969A1 (en) 2021-08-02 2024-06-12 Pfizer Inc. Improved expression vectors and uses thereof
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
CN116554303A (zh) 2022-01-30 2023-08-08 斯莱普泰(上海)生物医药科技有限公司 载脂蛋白E的C端片段及其在抑制γ分泌酶酶活中的应用
EP4473096A1 (en) 2022-02-02 2024-12-11 Pfizer Inc. Cysteine prototrophy
WO2024148328A2 (en) 2023-01-06 2024-07-11 Aptevo Research And Development Llc Bispecific pd-l1 and cd40 binding molecules and uses thereof
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures
WO2024259220A1 (en) 2023-06-15 2024-12-19 Theripion, Inc. Pon3 and evolved pon1 fusion polypeptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0009930B2 (en) * 1978-10-10 1988-08-24 The Board Of Trustees Of The Leland Stanford Junior University Recombinant dna, method for preparing it and production of foreign proteins by unicellular hosts containing it
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU546577B2 (en) * 1980-02-25 1985-09-05 Trustees Of Columbia University, The Use of eucaryotic promoter sequences in the production of proteinaceous materials
EP0054223A3 (en) * 1980-12-08 1983-01-12 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Plasmid vectors for eukaryotic cells and method for selecting transfected eukaryotic cells
FR2500847B1 (fr) * 1981-03-02 1985-09-13 Pasteur Institut Marqueurs genetiques selectifs pour cellules eucaryotes, procede de mise en oeuvre de tels marqueurs et application des cellules contenant un tel marqueur a la fabrication de proteines determinees apres leur transformation par un adn correspondant
AR241654A1 (es) * 1982-05-05 1992-10-30 Genentech Inc Procedimiento para producir activador de plasminogeno de tejido humano.
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
IE56716B1 (en) * 1983-01-19 1991-11-20 Genentech Inc Method for producing human tpa and expression vectors therefor
US4670399A (en) * 1983-01-31 1987-06-02 Stauffer Chemical Co. Hybrid plasmid with marker

Also Published As

Publication number Publication date
JP2557605B2 (ja) 1996-11-27
EP0117058B1 (en) 1989-09-20
AU578011B2 (en) 1988-10-13
EP0117058A3 (en) 1986-02-12
AU2353184A (en) 1984-07-26
KR840007253A (ko) 1984-12-06
DK173928B1 (da) 2002-02-25
IE55852B1 (en) 1991-01-30
JPS59173096A (ja) 1984-09-29
US4713339A (en) 1987-12-15
JPH06165672A (ja) 1994-06-14
JP2719512B2 (ja) 1998-02-25
ATE46536T1 (de) 1989-10-15
ES8507179A1 (es) 1985-09-01
IE840095L (en) 1984-07-19
ZA84377B (en) 1985-02-27
DE3479815D1 (en) 1989-10-26
ES529022A0 (es) 1985-09-01
EP0117058A2 (en) 1984-08-29
DK20984A (da) 1984-07-20
CA1301675C (en) 1992-05-26
JPH08252091A (ja) 1996-10-01
JPH0630609B2 (ja) 1994-04-27
NZ206841A (en) 1987-06-30

Similar Documents

Publication Publication Date Title
DK20984D0 (da) Fremgangsmade til fremstilling af et oensket modent protein i en hvirveldyrvaertscelle,polycistromisk udtrykkelsesvektor for det oenskede protein, fremgangsmade til selektering af transfilerede hvirveldyrceller og hvirveldyrcellekultur transformeret med vektoren
DK547185D0 (da) Vektorer til ekspression af hirudin, transformerede celler og fremgangsmaade til fremstilling af hirudin
DK0815246T3 (da) Fremgangsmåder og sammensætninger til sekretion af heterologe polypeptider
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
DK13788A (da) Fremgangsmaade til fremstilling af et polypeptid
DK520784D0 (da) Cycliske polypeptider, deres fremstilling og anvendelse
HK129394A (en) Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor
EP0452413A4 (en) Generation and selection of novel dna-binding proteins and polypeptides
ES8705467A1 (es) Un procedimiento para producir la proteina apoacuorina
DK645887D0 (da) Gamma-hesteinterferon, fremgangsmaade til fremstilling af, samt anvendelse af en saadan forbindelse
DK491487A (da) Dna-sekvens til ekspressionering af biologisk aktivt faktor xiii og anvendelse af samme
IL111479A0 (en) Chimeric proteins comprising borrelia polypetides and uses therefor
DK432987A (da) Fremgangsmaade til forbedring af ekspressionen af eukaryotprotein
DK572284D0 (da) Dna, der indkoder kanintnf, vektor med det deri indsatte dna, vaert transformeret med vektoren, kanintnfpolypeptid og fremgangsmaade til fremstilling af disse
ATE325815T1 (de) Menschliches neurotrimin-homolog
ES8802399A1 (es) Un procedimiento para la preparacion de un plasmido que se replica autonomamente en e. coli.
DE69227589D1 (de) Ecdysteroid-abhängige gen regulierung in säugetier-zellen
LV10491A (lv) SAF polipeptids gens promoters un to pielietojums ekspresijai STREPTOMYCES sunas
ATE92961T1 (de) Dns-sequenz.
DE3751757D1 (de) Autonom replizierende DNA Fragmente aus Säugerzellen mit Affinität zu DNA bindenden Proteinen
DK145595A (da) Fremgangsmåde til selektion af transficerede hvirveldyrceller
DK577283D0 (da) Gen kodet for interleukin-2-polypeptid,rekombinant dna baerende dette gen,levende cellelinie indeholdende dette rekombinante dna og fremgangsmaade til fremstilling af interleukin-2 ved anvendelse af denne cellelinie
DK1071798T3 (da) Konstruktioner til reguleret ekspression af rekombinante gener i prokaryote celler

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed
PGE Re-establishment of rights: approved
PUP Patent expired